Table 2.
a Performance per plane in the INTERGROWTH-21st internal validation set.
| Algorithm performance | ||||||
|---|---|---|---|---|---|---|
| HC plane only | AC plane only | FL plane only | MultiPlane (HC+AC+FL) | |||
| INTERGROWTH-21st (Test set) | GA 13+0–42+0 weeks (424 patients) | MAE (days) | ±4.5 | ±5.8 | ±6.0 | ±3.5 |
| 95% CI for MAE | (4.4–4.6) | (5.8–5.9) | (5.8–6.1) | (3.4–3.7) | ||
| R2 | 0.99 | 0.98 | 0.98 | 0.99 | ||
| Estimated GA within ± 1 week of GA estimated by gold standard (%) | 81.0% | 70.4% | 70.3% | 90.7% | ||
| Estimated GA within ± 2 weeks of GA estimated by gold standard (%) | 97.3% | 93.2% | 93.3% | 98.9% | ||
| GA 18+0–27+6 weeks (419 patients) | MAE (days) | ±3.9 | ±5.2 | ±5.3 | ±3.0 | |
| 95% CI for MAE | (3.8–4.0) | (5.1–5.3) | (5.2–5.5) | (2.9–3.2) | ||
| R2 | 0.94 | 0.89 | 0.88 | 0.96 | ||
| Estimated GA within ± 1 week of GA estimated by gold standard (%) | 86.9% | 75.3% | 74.8% | 94.5% | ||
| Estimated GA within ± 2 weeks of GA estimated by gold standard (%) | 99.2% | 96.1% | 97.1% | 99.7% | ||
| GA 28+0–42+0 weeks (424 patients) | MAE (days) | ±5.3 | ±6.9 | ±7.1 | ±4.3 | |
| 95% CI for MAE | (5.2–5.4) | (6.8–7.1) | (6.9–7.3) | (4.1–4.5) | ||
| R2 | 0.91 | 0.85 | 0.85 | 0.94 | ||
| Estimated GA within ± 1 week of GA estimated by gold standard (%) | 73.0% | 61.2% | 61.7% | 85.6% | ||
| Estimated GA within ± 2 weeks of GA estimated by gold standard (%) | 95.1% | 89.0% | 88.5% | 98.0% | ||
| b Performance per plane in the INTERBIO-21st external validation set | ||||||
|---|---|---|---|---|---|---|
| Algorithm performance | ||||||
| HC plane only | AC plane only | FL plane only | MultiPlanea (HC+AC+FL) | |||
| INTERBIO-21st | GA 13+0–42+0 weeks (2443 Patients) | MAE (days) | ±5.0 | ±6.1 | ±7.0 | ±4.1 |
| 95% CI for MAE | (4.9–5.0) | (6.1–6.2) | (6.9–7.0) | (4.0–4.2) | ||
| R2 | 0.98 | 0.97 | 0.95 | 0.99 | ||
| Estimated GA within ± 1 week of GA estimated by gold standard (%) | 75.7% | 66.7% | 62.5% | 85.1% | ||
| Estimated GA within ± 2 weeks of GA estimated by gold standard (%) | 96.3% | 92.1% | 89.7% | 98.2% | ||
| GA 18+0–27+6 weeks (1893 patients) | MAE (days) | ±4.6 | ±5.8 | ±6.5 | ±3.7 | |
| 95% CI for MAE | (4.5–4.6) | (5.7–5.9) | (6.4–6.7) | (3.6–3.9) | ||
| R2 | 0.91 | 0.86 | 0.79 | 0.94 | ||
| Estimated GA within ± 1 week of GA estimated by gold standard (%) | 79.8% | 68.6% | 64.1% | 88.1% | ||
| Estimated GA within ± 2 weeks of GA estimated by gold standard (%) | 97.5% | 93.7% | 91.5% | 98.8% | ||
| GA 28+0–42+0 weeks (1942 patients) | MAE (days) | ±5.9 | ±7.3 | ±8.0 | ±5.0 | |
| 95% CI for MAE | (5.8–5.9) | (7.2–7.4) | (7.8–8.2) | (4.8–5.1) | ||
| R2 | 0.86 | 0.77 | 0.69 | 0.90 | ||
| Estimated GA within ± 1 week of GA estimated by gold standard (%) | 67.3% | 58.6% | 55.4% | 78.1% | ||
| Estimated GA within ± 2 weeks of GA estimated by gold standard (%) | 93.9% | 87.7% | 85.8% | 96.9% | ||
Table showing the performance per plane (HC only, AC only, FL only, and MultiPlane) in the INTERGROWTH-21st test set (2a) and the INTERBIO-21st external validation set (2b).
HC Head Circumference, AC Abdominal Circumference, FL Femur Length, MAE Mean Absolute Error, CI Confidence Interval.
aAs not all planes were available for all participants, MultiPlane is based on 2304 participants.